LUX-Lung 8 A randomised, open-label phase III trial of afatinib versus erlotinib in patients with advanced squamous cell carcinoma of the lung as second-line. - ppt download
Patients with Brain Metastases | Afatinib NSCLC Trials | InOncology
Overview of the LUX-Lung clinical trial program of afatinib for non-small cell lung cancer - Cancer Treatment Reviews
researchopenworld.com
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials - The Lancet Oncology
Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases - Journal of Thoracic Oncology
LUX Lung 3 Clinical Trial Infographic (Boehringer Ingelheim) | Clinical trials, Boehringer ingelheim, Trials
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6 - The Lancet Oncology
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial - Annals of Oncology
mNSCLC with EGFR del19 Mutation | GILOTRIF® (afatinib)
Overall survival LUX-Lung 3 and LUX-Lung 6 (patients with Del19 and... | Download Scientific Diagram
First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials - Lung Cancer
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials - The Lancet Oncology
InOncology | LUX-Lung 3 Clinical Trial | Afatinib NSCLC Trials & Studies | Boehringer Ingelheim
LUX-Lung 3 clinical trial - ppt download
InOncology | LUX-Lung 3 Clinical Trial | Afatinib NSCLC Trials & Studies | Boehringer Ingelheim
Tyrosine Kinase Inhibitors for the Treatment of EGFR Mutation-Positive Non–Small-Cell Lung Cancer: A Clash of the Generations - Clinical Lung Cancer
EGFR-mutation-positive NSCLC: expanding the data pool for established treatment options - memoinOncology
LUX-Lung 7 slide kit
EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6 | British Journal of Cancer
mNSCLC with EGFR del19 Mutation | GILOTRIF® (afatinib)
Symptom and Quality of Life Improvement in LUX-Lung 6: An Open-Label Phase III Study of Afatinib Versus Cisplatin/Gemcitabine in Asian Patients With EGFR Mutation-Positive Advanced Non–small-cell Lung Cancer - Journal of Thoracic
Evaluation of the VeriStrat® serum protein test in patients with advanced squamous cell carcinoma of the lung treated with second-line afatinib or erlotinib in the phase III LUX-Lung 8 study - Lung
